Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus

Background: Exenatide is a subcutaneously injected incretin mimetic. It is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus (T2DM) who are already receiving therapy with metformin, a sulfonylurea, or both but continue to have suboptimal glycemic c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2006-05, Vol.28 (5), p.652-665
Hauptverfasser:	Iltz, Jason L., Baker, Danial E., Setter, Stephen M., Keith Campbell, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Blood Glucose - analysis Diabetes diabetes mellitus Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Disease control Drug dosages Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinology Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance exenatide exendin-4 Fasting GLP-1 Glucagon Glucagon-Like Peptide 1 - agonists glucagon-like peptide-1 Glucose Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use incretin mimetic Injections, Subcutaneous Insulin Insulin - metabolism Medical sciences Metformin - therapeutic use Peptides Peptides - pharmacology Pharmacokinetics Pharmacology. Drug treatments Pharmacy Sulfonylurea Compounds - therapeutic use type 2 diabetes Venoms - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!